secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001558370-23-011769
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu submits Cotempla XR-ODT site transfer PAS to FDA; expects 15% margin improvement on ADHD brands
--------------------------------------------------------------------------------

- Submitted Cotempla XR-ODT Prior Approval Supplement to FDA; expects six-month review with approval by late 2023/early 2024.
- Adzenys XR-ODT site transfer PAS already approved; production shifting to contract manufacturer.
- Upon completion of both site transfers, expects ~15% margin improvement for ADHD product line.
- CEO states outsourced manufacturing of Adzenys and Cotempla expected to begin by late 2023/early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023011769/0001558370-23-011769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023011769/aytu-20230710x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-011769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer